ArticleVirology journal2026
MG132-mediated inhibition of rabies virus replication via the Nrf2/SQSTM1/PINK1/Parkin autophagy pathway.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rabies virus (RABV), a fatal neurotropic virus, still lacks effective antiviral drugs for treatment once symptoms appear. MG132 acts as a novel therapeutic agent against viral infection, inhibits the degradation of nuclear factor erythroid-derived 2-like 2 (Nfe2l2; Nrf2), and enhances SQSTM1 expression in mouse hypothalamic organotypic cultures. Rapamycin-induced autophagy and Parkin-mediated mitophagy could also be inhibited by MG132. Autophagy signaling was triggered by RABV replication, but the antiviral effects of MG132 against RABV remained unclear. Here, we showed that MG132 exerted potent inhibitory activity against different viral strains (CVS-11 and CTN strains), with an efficacy comparable to that of ribavirin and higher than that of T705 in vitro. We further demonstrated that MG132 inhibited RABV replication by disrupting the Nrf2/SQSTM1/PINK1/Parkin pathway, with SQSTM1 acting as a key mediator. MG132 also prevented SQSTM1 degradation and enhanced colocalization between SQSTM1 and PINK1/Parkin. In vivo, MG132 (10 mg/kg) attenuated body weight loss and prolonged survival of RABV-infected mice by 40%. Overall, our findings indicated that MG132 inhibits RABV replication via the Nrf2/SQSTM1/PINK1/Parkin-related autophagy pathway and merits further investigation as an potential anti-RABV drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.